Therapeutic Effects of a Novel Fusion of ALT-803, an IL-15 Superagonist, with 4 Single-Chains of Anti-CD20 Antibody (2B8T2M) in Combination with Expanded Natural Killer Cells Against Rituximab Sensitive and Resistant Burkitt Lymphoma (BL)
Document Type
Abstract
Publication Date
2-2018
Journal Title
Journal of Clinical Oncology
Department
Pediatrics
Second Department
Health Behavior and Community Health
Recommended Citation
Chu, Y., Su, N., Alter, S., Jeng, E. K., Rhode, P. R., Barth, M., Lee, D., Wong, H. C., & Cairo, M. S. (2018). Therapeutic Effects of a Novel Fusion of ALT-803, an IL-15 Superagonist, with 4 Single-Chains of Anti-CD20 Antibody (2B8T2M) in Combination with Expanded Natural Killer Cells Against Rituximab Sensitive and Resistant Burkitt Lymphoma (BL). Journal of Clinical Oncology, 36 (Suppl.5), 32. Retrieved from https://touroscholar.touro.edu/nymc_fac_abstracts/224
COinS
